Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gary I. Gorodokin"'
Autor:
Gary I. Gorodokin, Denis A. Fedorenko, Vladimir Y. Melnichenko, Kira A Kurbatova, Andrei A. Novik, Jury L. Shevchenko, Tatyana Ionova, Alexey N. Kuznetsov
Publikováno v:
Annals of Hematology. 94:1149-1157
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is a promising approach to treatment of multiple sclerosis (MS) patients. In this paper, we present the long-term outcomes of a prospective sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d89ab3c02aaaced3ee7aea72b35749d
https://doi.org/10.1007/s00277-015-2337-8
https://doi.org/10.1007/s00277-015-2337-8
Autor:
Andrei V. Kartashov, Jury L. Shevchenko, Kira A Kurbatova, Andrei A. Novik, Denis A. Fedorenko, Vladimir Y. Melnichenko, Tatyana Ionova, Gary I. Gorodokin, Alexey N. Kuznetsov
Publikováno v:
Experimental Hematology. 40:892-898
High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. In this article, we present the results of a prospective phase II open-label sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373cbc7e7ae044e37b0b328eda1cb955
https://doi.org/10.1016/j.exphem.2012.07.003
https://doi.org/10.1016/j.exphem.2012.07.003
Autor:
Vladimir Y. Melnichenko, Igor A. Lisukov, Andrei A. Novik, Yury L. Shevchenko, Sergei V. Shamanski, Oleg A. Rykavicin, Boris V. Afanasiev, Denis A. Fedorenko, Gary I. Gorodokin, Aleksey N. Kuznetsov, Alexander D. Kulagin, Tatyana Ionova, Roman Ivanov, Vladimir A. Kozlov
Publikováno v:
Experimental Hematology. 36:922-928
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is a new and promising approach to the treatment of multiple sclerosis (MS) patients because currently there are no effective treatment met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf437364d721b2ed323f9cde00840068
https://doi.org/10.1016/j.exphem.2008.03.001
https://doi.org/10.1016/j.exphem.2008.03.001
Autor:
G.N. Bisaga, Roman Ivanov, Gary I. Gorodokin, A. V. Kishtovich, Tatyana Ionova, Andrei A. Novik, Denis A. Fedorenko
Publikováno v:
Cytotherapy. 7(4)
During the last several years high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) has been established as a therapeutic option for multiple sclerosis (MS) patients. We report on the long-term effects of HDCT + ASCT in two f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51465b55302e3bf789f68a0f9c5d15bf
https://pubmed.ncbi.nlm.nih.gov/16162458
https://pubmed.ncbi.nlm.nih.gov/16162458
Autor:
Tatyana Nikitina, Tatyana Ionova, Svetlana A. Kalyadina, Gary I. Gorodokin, Andrei A. Novik, Denis A. Fedorenko, NE Mochkin, Kira A Kurbatova
Publikováno v:
Blood. 116:4757-4757
Abstract 4757 Increased importance should be placed on the comprehensive symptom assessment in patients with multiple myeloma to accurately document the broad range of physical and psychological disease manifestations given from the patient perspecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::410c3c221d29ecc8d0d0380da76e43d4
https://doi.org/10.1182/blood.v116.21.4757.4757
https://doi.org/10.1182/blood.v116.21.4757.4757
Autor:
Vladimir Y. Melnichenko, Aleksey N. Kuznetsov, Gary I. Gorodokin, Andrei A. Novik, Andrei V. Kartashov, Kira A Kurbatova, Denis A. Fedorenko, Tatyana Ionova
Publikováno v:
Blood. 116:372-372
Abstract 372 High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (ASCT) offers promising results in the treatment of multiple sclerosis (MS) patients. Reduced intensity conditioning regimens (mini-ASCT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::864a69277d3ceed34ff467e11ab78729
https://doi.org/10.1182/blood.v116.21.372.372
https://doi.org/10.1182/blood.v116.21.372.372
Autor:
Gary I. Gorodokin, Tatyana Ionova, Andrei A. Novik, Denis A. Fedorenko, Tatyana Nikitina, NE Mochkin, Kira A Kurbatova, Svetlana A. Kalyadina
Publikováno v:
Blood. 116:2561-2561
Abstract 2561 Comprehensive symptom assessment before and during treatment in lymphoma patients is worthwhile. We aimed to develop a new symptom assessment tool — Comprehensive Symptom Profile in Lymphoma Patients (CSP-Lym) and test its applicabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c523046a21b6bccb243f7b6bffa19f4
https://doi.org/10.1182/blood.v116.21.2561.2561
https://doi.org/10.1182/blood.v116.21.2561.2561
Autor:
Andrey E. Zdorov, Boris V. Afanasiev, Inna V. Vereschagina, Yury N. Fedotov, Oleg A. Rykavicin, Olga A. Malysheva, Yury L. Shevchenko, Tatiana I. Ionova, Anton V. Kishtovich, Andrei A. Novik, Alexey N. Kuznetcov, Alexandr A. Myasnikov, Gary I. Gorodokin, Roman Ivanov, Nikolay I. Baziy, Igor A. Lisukov, Denis A. Fedorenko, Andrey D. Kulagin, Sergey V. Shamanski, Vladimir Y. Melnichenko
Publikováno v:
Blood. 108:3072-3072
During the last decade HDCT+ASCT is more often used as a therapeutic option for MS patients. The major treatment outcomes for MS patients are disease-progressive free period and improvement of patient’s quality of life (QoL). We aimed to study trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a17da5256087bd6d3e8c766f892a2af2
https://doi.org/10.1182/blood.v108.11.3072.3072
https://doi.org/10.1182/blood.v108.11.3072.3072
Autor:
Yury L. Shevchenko, Inna V. Vereschagina, Vladimir Melnichenko, Andrei D. Kulagin, Gennady N. Bisaga, Gary I. Gorodokin, Boris V. Afanasiev, Yury N. Fedotov, Anton V. Kishtovich, Andrei A. Novik, Tatiana I. Ionova, Igor A. Lisukov, Denis A. Fedorenko, Olga A. Malysheva, Sergei Voloshin
Publikováno v:
Blood. 106:5467-5467
HDCT+ASCT is a new and promising therapy for MS patients. Among a number of unclear questions is the terms of conducting HDCT+ASCT. According to our concept there are 3 strategies of HDCT+ASCT depending on the terms of disease process: early, convent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab88e1e5db1346fecf7e58e6055ed96
https://doi.org/10.1182/blood.v106.11.5467.5467
https://doi.org/10.1182/blood.v106.11.5467.5467
Autor:
Natalia N. Malakchova, Julia K. Lebedeva, Nina E. Osipova, Tatiana I. Ionova, Mikhail V. Kopp, Alexander Myasnikov, Tatiana V. Chagorova, Gary I. Gorodokin, Anton V. Kishtovich, Andrei A. Novik, Denis A. Fedorenko, Anastasia V. Pankova
Publikováno v:
Blood. 106:4651-4651
The population of new ANHL patients is heterogeneous in terms of their biological parameters and the IPI scoring system is widely used to make the disease prognosis. Recently heterogeneity of ANHL patients in terms of their QoL has been shown. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33c8ee4ee28a378ad929aa40e19403bb
https://doi.org/10.1182/blood.v106.11.4651.4651
https://doi.org/10.1182/blood.v106.11.4651.4651